利奈唑胺联合左氧氟沙星治疗耐药肺结核的临床效果与安全性分析

Analysis on Clinical Effect and Safety of Linezolid Combined with Levofloxacin in the Treatment of Drug-Resistant Pulmonary Tuberculosis

目的探讨利奈唑胺联合左氧氟沙星治疗耐药肺结核的临床效果与安全性。方法选择2018年6月至2021年3月我院收治的66例耐药肺结核患者,编号后按照双盲、随机抽签法分为对照组(n=33)和观察组(n=33)。两组均给予常规化疗,同时对照组给予左氧氟沙星治疗,观察组给予左氧氟沙星联合利奈唑胺治疗。比较两组患者病情改善情况、血清指标及不良反应发生率。结果治疗6个月后,观察组病灶吸收缩小、空洞闭合、痰培养转阴占比高于对照组(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均高于对照组(P<0.05)。观察组不良反应发生率为24.2%,与对照组的15.2%比较差异无统计学意义(P>0.05)。结论利奈唑胺联合左氧氟沙星可促进耐药肺结核患者病情改善,提高患者的免疫功能,且安全性较高。

Objective To explore the clinical effect and safety of linezolid combined with levofloxacin in the treatment of drug-resistant pulmonary tuberculosis.Methods 66 patients with drug-resistant pulmonary tuberculosis admitted to our hospital from June 2018 to March 2021 were selected and randomly divided into control group(n=33)and observation group(n=33).Both groups were given routine chemotherapy.The control group was treated with levofloxacin,and the observation group was treated with levofloxacin combined with linezolid.The disease condition improvement,serum indicators and the incidence of adverse reactions were compared between the two groups.Results After 6 months of treatment,the rates of reduced focus absorption,cavity closure and negative sputum culture in the observation group were higher than those in the control group(P<0.05).After treatment,the CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)of the observation group were higher than those of the control group(P<0.05).The incidence of adverse reactions in the observation group was 24.2%,which had no statistical difference with 15.2% in the control group(P>0.05).Conclusions Linezolid combined with levofloxacin can improve the disease condition and immune function of patients with drug-resistant pulmonary tuberculosis,with higher safety.